Inventor
VORONINA VERA
US32 patents
Patents
32 patentsUS8847005B2Sep 30, 2014
Genetically modified major histocompatibility complex mice
REGENERON PHARMA33 citations98
US9113616B2Aug 25, 2015
Genetically modified mice having humanized TCR variable genes
REGENERON PHARMA67 citations97
US9043996B2Jun 2, 2015
Genetically modified major histocompatibility complex animals
REGENERON PHARMA31 citations94
US10154658B2Dec 18, 2018
Genetically modified major histocompatibility complex mice
REGENERON PHARMA16 citations93
US9615550B2Apr 11, 2017
Genetically modified major histocompatibility complex mice
REGENERON PHARMA12 citations84
US9591835B2Mar 14, 2017
Genetically modified major histocompatibility complex animals
REGENERON PHARMA11 citations84
US9585373B2Mar 7, 2017
Genetically modified major histocompatibility complex mice
REGENERON PHARMA8 citations84
US11528895B2Dec 20, 2022
Genetically modified T cell receptor mice
REGENERON PHARMA2 citations73
US11219195B2Jan 11, 2022
Genetically modified major histocompatibility complex mice
REGENERON PHARMA1 citations73
US10986822B2Apr 27, 2021
Genetically modified major histocompatibility complex mice
REGENERON PHARMA1 citations73
US10869466B2Dec 22, 2020
Genetically modified major histocompatibility complex mice
REGENERON PHARMA2 citations73
US10820581B2Nov 3, 2020
Humanized T cell co-receptor mice
REGENERON PHARMA1 citations73
US10457960B2Oct 29, 2019
Methods and compositions for targeted genetic modification using paired guide RNAs
REGENERON PHARMA5 citations73
US10219493B2Mar 5, 2019
Genetically modified major histocompatibility complex mice
REGENERON PHARMA1 citations73
US10820582B2Nov 3, 2020
Non-human animals having an engineered immunoglobulin Λ light chain locus
REGENERON PHARMA3 citations71
US12553064B2Feb 17, 2026
Methods and compositions for targeted genetic modification through single-step multiple targeting
REGENERON PHARMA0 citations63
US12414551B2Sep 16, 2025
Genetically modified major histocompatibility complex mice
REGENERON PHARMA0 citations63
US11326184B2May 10, 2022
Methods and compositions for targeted genetic modification through single-step multiple targeting
REGENERON PHARMA1 citations63
US11224208B2Jan 18, 2022
Genetically modified major histocompatibility complex mice
REGENERON PHARMA0 citations63
US12582105B2Mar 24, 2026
Genetically modified T cell receptor mice
REGENERON PHARMA0 citations62
US11697828B2Jul 11, 2023
Methods and compositions for targeted genetic modification using paired guide RNAs
REGENERON PHARMA1 citations62
US11576984B2Feb 14, 2023
Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
REGENERON PHARMA1 citations62
US10779520B2Sep 22, 2020
Genetically modified major histocompatibility complex animals
REGENERON PHARMA1 citations62
US10314296B2Jun 11, 2019
Genetically modified major histocompatibility complex mice
REGENERON PHARMA1 citations62
US12433264B2Oct 7, 2025
Non-human animals having an engineered immunoglobulin lambda light chain locus
REGENERON PHARMA0 citations61
US12295354B2May 13, 2025
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
REGENERON PHARMA0 citations61
US12082566B2Sep 10, 2024
Rodent animals expressing human CR1
REGENERON PHARMA0 citations61
US10980221B2Apr 20, 2021
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
REGENERON PHARMA0 citations61
US10045516B2Aug 14, 2018
Genetically modified major histocompatibility complex animals
REGENERON PHARMA1 citations52
US9700025B2Jul 11, 2017
Genetically modified major histocompatibility complex animals
REGENERON PHARMA1 citations52
US12371475B2Jul 29, 2025
Nucleic acids encoding anchor modified antibodies and uses thereof
REGENERON PHARMA0 citations51
US12342801B2Jul 1, 2025
Methods for producing antigen-binding proteins against foreign antigens
REGENERON PHARMA0 citations49